THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
▪ Abstract The taxane class of antimicrotubule anticancer agents is perhaps the most important addition to the chemotherapeutic armamentarium against cancer over the past several decades. After only a brief period, the taxanes have not only demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head and neck, bladder, and esophagus, they have also demonstrated effectiveness in the initial therapy of earlier stages of cancer, a setting in which any new therapy is likely to make its greatest impact. The challenge now facing investigators is to develop strategies to maximize therapeutic benefits with the taxanes in the early stages, as well as the advanced stages, of many cancers. This review describes the preclinical features and clinical results of the two major taxanes, paclitaxel (Taxol®, Bristol-Myers Squibb) and docetaxel (Taxotere®, Rhone-Poulenc Rhorer).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Self-citationHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., & Wilson, L. (1996) · PubMed · Cited by 770
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
Ringel, I., & Horwitz, S. B. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.288 · Cited by 677
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
Haldar, S., Chintapalli, J., & Croce, C. M. (1996) · PubMed · Cited by 651
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Taxol: an antimitotic agent with a new mechanism of action
Manfredi, J. J., & Horwitz, S. B. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90025-1 · Cited by 483
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.384 · Cited by 429
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Cortes, J. E., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2643 · Cited by 421
Taxol: Mechanisms of Action and Resistancea
HORWITZ, S. B., LOTHSTEIN, L., MANFREDI, J. J., MELLADO, W., PARNESS, J., ROY, S. N., SCHIFF, P. B., SORBARA, L., & ZEHEB, R. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb38455.x · Cited by 416
Diaz, J. F., & Andreu, J. M. (1993) · Biochemistry · doi:10.1021/bi00062a003 · Cited by 411
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Taxol: the first of the taxanes, an important new class of antitumor agents.
Rowinsky, E. K., Onetto-Pothier, N., Canetta, R. M., & Arbuck, S. G. (1992) · PubMed · Cited by 389
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., & Barrett, R. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1748 · Cited by 372
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Rowinsky, E. K., Donehower, R. C., Jones, R. J., & Tucker, R. W. (1988) · PubMed · Cited by 368
Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994) · Annals of Neurology · doi:10.1002/ana.410350310 · Cited by 363
Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., & Johnson, D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.388 · Cited by 336
Bissery, M.-C., Nohynek, G., Sanderink, G.-J., & Lavelie, F. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199506000-00001 · Cited by 323
Ravdin, P. M., Burris, H. A., Cook, G., Eisenberg, P., Kane, M., Bierman, W. A., Mortimer, J., Genevois, E., & Bellet, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2879 · Cited by 317
Roth, B. J., Dreicer, R., Einhorn, L. H., Neuberg, D., Johnson, D. H., Smith, J. L., Hudes, G. R., Schultz, S. M., & Loehrer, P. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2264 · Cited by 317
Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V, ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2127 · Cited by 308
Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., & Ozols, R. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1860 · Cited by 295
Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus
Ajani, J. A., Ilson, D. H., Daugherty, K., Pazdur, R., Lynch, P. M., & Kelsen, D. P. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.14.1086 · Cited by 280
Trimble, E. L., Adams, J. D., Vena, D., Hawkins, M. J., Friedman, M. A., Fisherman, J. S., Christian, M. C., Canetta, R., Onetto, N., & Hayn, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.12.2405 · Cited by 267
Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D., & Goldberg, G. L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1748 · Cited by 263
Fossella, F. V., Lee, J. S., Shin, D., Calayag, M. D., Huber, M., Perez-Soler, R., Murphy, W. K., Lippman, S. M., Benner, S. E., & Glisson, B. S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.645 · Cited by 254
3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin.
Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., & Horwitz, S. B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41836-9 · Cited by 245
Reichman, B. S., Seidman, A. D., Crown, J. P., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V, & Hudis, C. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237
Chevallier, B., Fumoleau, P., Kerbrat, P., Dieras, V, Roche, H., Krakowski, I., Azli, N., Bayssas, M., Lentz, M. A., & Van Glabbeke, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.314 · Cited by 222
Marre, F., Sanderink, G., de Sousa, G., et al. (1996) · PubMed · Cited by 221
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Fossella, F. V., Lee, J. S., Murphy, W. K., Lippman, S. M., Calayag, M., Pang, A., Chasen, M., Shin, D. M., Glisson, B., & Benner, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1238 · Cited by 221
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
McGuire, W. P., Blessing, J. A., Moore, D. H., Lentz, S. S., & Photopulos, G. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.792 · Cited by 217
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Francis, P. A., Rigas, J. R., Kris, M. G., Pisters, K. M., Orazem, J. P., Woolley, K. J., & Heelan, R. T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1232 · Cited by 216
Wilson, W. H., Berg, S. L., Bryant, G., Wittes, R. E., Bates, S., Fojo, A., Steinberg, S. M., Goldspiel, B. R., Herdt, J., & O'Shaughnessy, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1621 · Cited by 216
Seidman, A. D., Reichman, B. S., Crown, J. P., Yao, T. J., Currie, V, Hakes, T. B., Hudis, C. A., Gilewski, T. A., Baselga, J., & Forsythe, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1152 · Cited by 205
Seidman, A. D., Tiersten, A., Hudis, C., Gollub, M., Barrett, S., Yao, T. J., Lepore, J., Gilewski, T., Currie, V, & Crown, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 203
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky, E. K., Burke, P. J., Karp, J. E., Tucker, R. W., Ettinger, D. S., & Donehower, R. C. (1989) · PubMed · Cited by 196
Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F. P., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.1.18 · Cited by 187
Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., & Reed, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1165 · Cited by 179
Motzer, R. J., Bajorin, D. F., Schwartz, L. H., Hutter, H. S., Bosl, G. J., Scher, H. I., Lyn, P., & Fischer, P. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2277 · Cited by 176
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis, P., Schneider, J., Hann, L., Balmaceda, C., Barakat, R., Phillips, M., & Hakes, T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2301 · Cited by 167
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
Hainsworth, J. D., Thompson, D. S., & Greco, F. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1609 · Cited by 160
for the ECTG (Early Clinical Trials Group of the EORTC), Cerny, T., Kaplan, S., Pavlidis, N., Schöffski, P., Epelbaum, R., van Meerbeek, J., Wanders, J., Franklin, H., & Kaye, S. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.311 · Cited by 160
Gianni, L., Munzone, E., Capri, G., Villani, F., Spreafico, C., Tarenzi, E., Fulfaro, F., Caraceni, A. T., Martini, C., Laffranchi, A., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.15.1169 · Cited by 144
Activity of docetaxel (Taxotere) in small cell lung cancer
Smyth, J. F., Smith, I. E., Sessa, C., Schöffski, P., Wanders, J., Franklin, H., & Kaye, S. B. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90455-3 · Cited by 139
Kunitoh, H., Watanabe, K., ONOSHI, T., Furuse, K., Niitani, H., & Taguchi, T. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1649 · Cited by 136
Choy, H., Akerley, W., Safran, H. P., Clark, J. R., Rege, V. B., Papa, A., Glantz, M., Puthawala, Y., Soderberg, C. H., & Leone, L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2682 · Cited by 132
Webster, L. K., Linsenmeyer, M. E., Millward, M., Morton, C. G., Bishop, J. F., & Woodcock, D. M. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1685 · Cited by 128
Paclitaxel pharmacokinetics and pharmacodynamics.
Kearns, C. M., Gianni, L., & Egorin, M. J. (1995) · PubMed · Cited by 126
Dumontet, C., Durán, G. E., Steger, K. A., Beketić-Orešković, L., & Sikic, B. I. (1996) · PubMed · Cited by 111
Optic Nerve Disturbances: a New Form of Paclitaxel Neurotoxicity
Capri, G., Munzone, E., Tarenzi, E., Fulfaro, F., Gianni, L., Caraceni, A. T., Martini, C., & Scaioli, V. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.14.1099 · Cited by 94
Rowinsky, E. K., Citardi, M. J., Noe, D. A., & Donehower, R. C. (1993) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01195344 · Cited by 92
Knick, V. C., Eberwein, D. J., & Miller, C. G. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.14.1072 · Cited by 70
Glantz, M., Choy, H., Kearns, C. M., Cole, B. F., Mills, P., Zuhowski, E. G., Saris, S. C., Rhodes, C. H., Stopa, E. G., & Egorin, M. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.600 · Cited by 61
Day, B. W., Rezenkran, H. S., Gunsekera, Z. S. P., Loungley, R. E., Lin, M. C., Hamel, E., Kowalski, R. P., & Haa, E. (1996) · Cited by 56
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
Wilson, W. H., Chabner, B. A., Bryant, G., Bates, S. E., Fojo, A. T., Regis, J. T., Jaffe, E. S., Steinberg, S. M., Goldspiel, B. R., & Cheson, B. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.381 · Cited by 52
de Wit, R., van der Burg, M. E. L., van de Gaast, A., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058942 · Cited by 42
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Younes, A., Sarris, A. H., Melnyk, A., Romaguera, J. E., McLaughlin, P. J., Swan, F., Rodriguez, M. A., Hagemeister, F. B., Moore, D., & North, L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.583 · Cited by 41
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751
Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together
Wang, T.-H., Wang, H.-S., & Soong, Y.-K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2619::aid-cncr26>3.0.co;2-j · Cited by 647
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Metadata
- Authors
- Rowinsky, M.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 1997-02
- Volume
- 48
- Issue
- 1
- Pages
- 353-374
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2154094988
- Cited by
- 721
- References
- 66
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.